APP and Alzheimer disease: With the levels of APP, BACE1 and ADAM10 remaining largely unaffected by the loss of SFRP1, the pathological features of AD in the mouse model thus appears to be directly and significantly influenced by glia-secreted SFRP1′s suppression of ADAM10’s non-amyloidogenic processing.